Alan Cornell

Title: Alan Cornell: Innovator in Pharmaceutical Chemistry

Introduction

Alan Cornell is a notable inventor based in Basingstoke, GB. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of selective receptor agonists. His work focuses on addressing various 5-HT associated disorders, which include obesity, obsessive-compulsive disorder, depression, and anxiety.

Latest Patents

Alan Cornell holds 1 patent for his invention related to 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines. This invention provides a formula that acts as selective 5-HT receptor agonists, which are crucial for the treatment of several mental health disorders. The specific formula includes various substituents, which are defined in the patent specification.

Career Highlights

Alan is currently employed at Eli Lilly and Company, a leading global pharmaceutical company. His role involves extensive research and development in the field of medicinal chemistry. His innovative approach has contributed to the advancement of therapeutic options for patients suffering from complex disorders.

Collaborations

Alan has collaborated with several talented professionals in his field, including Karin Briner and Anne Marie Camp. These collaborations have fostered a productive environment for innovation and have led to significant advancements in their research projects.

Conclusion

Alan Cornell's contributions to pharmaceutical chemistry exemplify the impact of innovative thinking in addressing critical health issues. His work continues to inspire advancements in treatment options for various disorders.